Condition
Lipoproteinemia
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Unknown2
Completed1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04247048Not ApplicableCompleted
Kinetic Study of Lp(a) and PCSK9 in Humans
NCT05181969UnknownPrimary
Long-term Characterization of Lipoprotein Apheresis Technologies for Individual Device Adaption (LOLIDA)
NCT04993664Not ApplicableWithdrawn
Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
NCT04613167Not ApplicableUnknown
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment
Showing all 4 trials